Algernon Pharmaceuticals Inc (AGNPF)

[nelskof]

medchem, can you help me here since you have more experience?

In the PR, the company states, "is pleased to announce that it plans to conduct an interim data review of its multi-national Ifenprodil"

If they haven't conducted the review then how would they know they have a strong signal?

I was originally taking this as a desperation move because there are delays with the trials and they have quite a few competitors reading out data and wrapping up late stage trials in December. Almost like a hail mary hoping the data is good to keep up with everyone else before they become irrelevant.

Help me out, please.